CD276 and non-small cell lung carcinoma: Therefore, with a promising application in NSCLC, B7H3-based drugs, such as oncolytic viruses, B7H3 blockades, ADCs, have shown pretty good antitumor efficacy accompanied by an increased number of CD8+ TILs, M1-polarized macrophages and immune cell reactivation [26, 43, 44].